Informações:
Falhas:
ID
34741
Descrição
Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients; ODM derived from: https://clinicaltrials.gov/show/NCT02324842
Link
https://clinicaltrials.gov/show/NCT02324842
Palavras-chave
Versões (1)
- 25/01/2019 25/01/2019 -
Titular dos direitos
See clinicaltrials.gov
Transferido a
25 de janeiro de 2019
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Type 2 Diabetes Mellitus NCT02324842
Eligibility Type 2 Diabetes Mellitus NCT02324842
- StudyEvent: Eligibility
Similar models
Eligibility Type 2 Diabetes Mellitus NCT02324842
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Age
Item
male and female subjects between the ages of 18-70
boolean
C0001779 (UMLS CUI [1])
Diabetes Mellitus, Non-Insulin-Dependent
Item
subjects with type 2 diabetes mellitus (t2dm)
boolean
C0011860 (UMLS CUI [1])
Pharmaceutical Preparations Absent | Metformin Dose Stable
Item
drug naïve or on stable dose (more than 3 months) of metformin
boolean
C0013227 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C0025598 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0205360 (UMLS CUI [2,3])
C0332197 (UMLS CUI [1,2])
C0025598 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0205360 (UMLS CUI [2,3])
Hemoglobin A1c measurement
Item
have an hba1c levels ≥7.0% and <10.0%
boolean
C0474680 (UMLS CUI [1])
Stable body weight Duration
Item
stable weight (± 3 lbs) over the preceding 3 months
boolean
C0517386 (UMLS CUI [1,1])
C0449238 (UMLS CUI [1,2])
C0449238 (UMLS CUI [1,2])
Pharmaceutical Preparations Affecting Glucose metabolism | Exception Metformin
Item
subjects taking drugs known to affect glucose metabolism (other than metformin) will be excluded.
boolean
C0013227 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C0596620 (UMLS CUI [1,3])
C1705847 (UMLS CUI [2,1])
C0025598 (UMLS CUI [2,2])
C0392760 (UMLS CUI [1,2])
C0596620 (UMLS CUI [1,3])
C1705847 (UMLS CUI [2,1])
C0025598 (UMLS CUI [2,2])
Proliferative diabetic retinopathy | Plasma creatinine measurement | Gender | Estimated Glomerular Filtration Rate
Item
individuals with evidence of proliferative diabetic retinopathy or plasma creatinine >1.4 females or >1.5 males or egfr< 60 ml/min.172m2 will be excluded
boolean
C0154830 (UMLS CUI [1])
C1278055 (UMLS CUI [2])
C0079399 (UMLS CUI [3])
C3811844 (UMLS CUI [4])
C1278055 (UMLS CUI [2])
C0079399 (UMLS CUI [3])
C3811844 (UMLS CUI [4])
Body Weight Unstable
Item
unstable body weight (change of greater than ±3 lbs over the preceding 3 months)
boolean
C0005910 (UMLS CUI [1,1])
C0443343 (UMLS CUI [1,2])
C0443343 (UMLS CUI [1,2])
Participation Exercise Very heavy
Item
participates in excessively heavy exercise program
boolean
C0679823 (UMLS CUI [1,1])
C0015259 (UMLS CUI [1,2])
C0439540 (UMLS CUI [1,3])
C0015259 (UMLS CUI [1,2])
C0439540 (UMLS CUI [1,3])